Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus CONZIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus CONZIP.
ASTRAMORPH PF vs CONZIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic